Currently, there are 158.76M common shares owned by the public and among those 72.17M shares have been available to trade.
The company’s stock has a 5-day price change of -0.43% and 25.59% over the past three months. IAS shares are trading -19.18% year to date (YTD), with the 12-month market performance down to -16.75% lower. It has a 12-month low price of $7.98 and touched a high of $17.53 over the same period. IAS has an average intraday trading volume of 1.16 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.93%, 11.16%, and -0.98% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Integral Ad Science Holding Corp (NASDAQ: IAS) shares accounts for 42.97% of the company’s 158.76M shares outstanding.
It has a market capitalization of $1.88B and a beta (3y monthly) value of 1.52. The stock’s trailing 12-month PE ratio is 836.69, while the earnings-per-share (ttm) stands at $0.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.60% over the week and 2.99% over the month.
Earnings per share for the fiscal year are expected to increase by 432.48%, and 56.12% over the next financial year.
Looking at the support for the IAS, a number of firms have released research notes about the stock. Loop Capital stated their Buy rating for the stock in a research note on April 30, 2024, with the firm’s price target at $15. Morgan Stanley coverage for the Integral Ad Science Holding Corp (IAS) stock in a research note released on April 16, 2024 offered a Equal-Weight rating with a price target of $12. Raymond James was of a view on February 28, 2024 that the stock is Outperform, while BofA Securities gave the stock Buy rating on January 11, 2024, issuing a price target of $19. BMO Capital Markets on their part issued Outperform rating on January 09, 2024.
